6OTG image
Entry Detail
PDB ID:
6OTG
Title:
HIV-1 protease triple mutants V32I, I47V, V82I with GRL-011-11A (a methylamine bis-Tetrahydrofuran P2-Ligand, sulfonamide isostere derivate)
Biological Source:
PDB Version:
Deposition Date:
2019-05-03
Release Date:
2019-05-29
Method Details:
Experimental Method:
Resolution:
1.50 Å
R-Value Free:
0.17
R-Value Work:
0.13
R-Value Observed:
0.13
Space Group:
P 21 21 2
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:Protease
Mutations:Q7K, V32I, L33I, I47V, L63I, C67A, V82I, C95A
Chain IDs:A, B
Chain Length:99
Number of Molecules:2
Biological Source:Human immunodeficiency virus 1
Primary Citation
Structural studies of antiviral inhibitor with HIV-1 protease bearing drug resistant substitutions of V32I, I47V and V82I.
Biochem.Biophys.Res.Commun. 514 974 978 (2019)
PMID: 31092330 DOI: 10.1016/j.bbrc.2019.05.064

Abstact

HIV-1 protease inhibitors are effective in HIV/AIDS therapy, although drug resistance is a severe problem. This study examines the effects of four investigational inhibitors against HIV-1 protease with drug resistant mutations of V32I, I47V and V82I (PRTri) that model the inhibitor-binding site of HIV-2 protease. These inhibitors contain diverse chemical modifications on the darunavir scaffold and form new interactions with wild type protease, however, the measured inhibition constants for PRTri mutant range from 17 to 40 nM or significantly worse than picomolar values reported for wild type enzyme. The X-ray crystal structure of PRTri mutant in complex with inhibitor 1 at 1.5 Å resolution shows minor changes in interactions with inhibitor compared with the corresponding wild type PR complex. Instead, the basic amine at P2 of inhibitor together with mutation V82I induces two alternate conformations for the side chain of Arg8 with new interactions with inhibitor and Leu10. Hence, inhibition is influenced by small coordinated changes in hydrophobic interactions.

Legend

Protein

Chemical

Disease

Primary Citation of related structures